Caribou Biosciences, Inc. (CRBU) vs Insight Molecular Diagnostics Inc. (IMDX)
A side-by-side comparison of Caribou Biosciences, Inc. and Insight Molecular Diagnostics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CRBU
Caribou Biosciences, Inc.
$1.18HealthcareDelayed quote: Oct 6, 2026, 10:44 AM EDT
IMDX
Insight Molecular Diagnostics Inc.
$3.65HealthcareDelayed quote: Oct 6, 2026, 10:44 AM EDT
Total return — CRBU vs IMDX
growth of $100 · dividends reinvested · last 5yCRBU -92.7% (-40.8%/yr)IMDX -96.7% (-49.5%/yr)CRBU compounded faster over this window
CRBU IMDX
CRBU vs IMDX: by the numbers
- •IMDX is the larger company ($118M vs $117M market cap).
- •Both run net losses; CRBU's is the smaller (-1030.42% vs -2955.63% net margin).
- •IMDX grew revenue faster over the past five years (27.24% vs -2.03% CAGR).
Metrics side by side
Valuation
| Metric | CRBU | IMDX |
|---|---|---|
| P/S ratio | 11.66 | 70.57 |
| P/B ratio | 1.19 | N/A |
Profitability
| Metric | CRBU | IMDX |
|---|---|---|
| Gross margin | 67.34% | 11.17% |
| Operating margin | -1220.49% | -754.08% |
| Net margin | -1030.42% | -2955.63% |
| ROE | -105.40% | N/A |
| ROIC | -87.72% | -223.06% |
Growth (annualized)
| Metric | CRBU | IMDX |
|---|---|---|
| Revenue CAGR (5Y) | -2.03% | 27.24% |
| Total return CAGR (5Y) | -44.43% | -44.39% |
Frequently asked
- Which has grown faster, CRBU or IMDX?
- Over the past five years, IMDX grew revenue faster — CRBU at a -2.03% CAGR versus IMDX at 27.24%.
Go deeper
Dig into the metrics
Caribou Biosciences ROEInsight Molecular Diagnostics ROECaribou Biosciences operating marginInsight Molecular Diagnostics operating marginCaribou Biosciences revenue growthInsight Molecular Diagnostics revenue growthCaribou Biosciences free cash flowInsight Molecular Diagnostics free cash flow
Caribou Biosciences & Insight Molecular Diagnostics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.